Navigation Links
Clinical Study Data Indicates that Celliant Reduces Pain
Date:6/25/2009

A just completed clinical study proves that revolutionary technical performance fiber actually reduces pain when worn in garments or slept on in bedding. Already proven to increase oxygen levels in the body, data from a new clinical study published in online journal BioMed Central (www.BioMedCentral.com) supports claims that Celliant reduces pain.

Santa Monica, CA (PRWEB) June 25, 2009 -- Already proven to increase oxygen levels in the body, data from a new clinical study published in online journal BioMedCentral.com supports claims that Celliant reduces pain.

Celliant is a specially formulated technical performance fiber designed to enhance oxygen levels in the body, aiding in comfort, healing, performance and overall wellness. Data analysis from a clinical study conducted by Robyn MB York and Ian L. Gordon, research scientists affiliated with Long Beach VA Healthcare System and UCI Medical Center, shows that the material also has potent pain relief capabilities. In a double blind study using measurement techniques successfully employed in FDA-supervised clinical trials of pain relief medications, the magnitude of pain relief reported by participants using products enhanced with Celliant was significantly greater than that reported by participants using placebo products. Hologenix, LLC, the company behind Celliant, sponsored the trials.

"We have completed a properly designed clinical trial which shows strong results in favor of Celliant," explains Seth Casden, CEO of Hologenix, LLC. "The results are statistically significant, providing clinical proof that products enhanced with Celliant actually reduce pain."

These results have obvious implications for the health and medical markets. However, Hologenix believes a broader market for their pain relieving textile exists.

"To date, much of the research conducted on Celliant has been limited to patients with diabetes, or some form of vascular impairment," explains Casden. "However, many individuals have trouble staying active because of chronic pain--virtually everyone suffers from some sort of ache or pain during their life."

In fact, this most recent study included subjects who suffered from diabetic neuropathic pain as well as a second group of non-diabetic subjects. Both groups experienced significant pain relief. The data showing a greater reduction in pain with Celliant was sufficiently strong that the research team is conducting a second, follow-up study to further measure the pain reduction and healing characteristics of Celliant.

"Personally, I was very surprised by the results. In doing these studies, you often hope for a positive result but, in this case, the data points overwhelmingly to Celliant reducing pain," stated Dr. Ian L. Gordon, PhD and head of Vascular Surgery at Long Beach VA Medical Center. "What we have here is a material that can be incorporated into any number of products--garments, bedding, socks, bandages, athletic wear--to non-invasively reduce pain. It's a very exciting moment for us as research scientists and for the medical and health community at large."

The technology behind Celliant is based on years of research regarding the effect of certain wavelengths of light on the body and wound healing. Past studies have shown that light can be used to reduce pain, speed healing, increase energy and improve overall wellness. Celliant is a polymer fiber containing optically active micro-particles - a proprietary mixture of natural materials - which scatter and reflect visible and near infrared light. Products constructed with such optically modified fibers are designed to scatter and reflect light and energy onto the underlying tissue and skin. Numerous anecdotal reports from patients with a variety of chronic pain syndromes indicate that wearing garments or sleeping on bedding containing Celliant led to dramatic improvement or complete resolution of pain. The goal of this study was to scientifically confirm and measure these results. The full study can be found here: Celliant Pain Study.

Hologenix, LLC, is currently conducting three additional clinical studies to further measure the effects of Celliant on sleep, athletic performance and health.

About Celliant
Celliant is a specially formulated fiber that is knit or woven into fabrics used in garments and bedding materials. Products containing Celliant have been clinically proven to enhance oxygen levels in the body and reduce pain. Increased oxygen levels have been clinically proven to relieve pain, promote quicker healing, improve sleep quality, heighten athletic performance and improve overall wellness. For more information about products that include Celliant, how Celliant works, or studies that have been conducted on Celliant, please visit www.celliant.com.

Products enhanced with Celliant have been clinically proven to relieve pain, increase comfort and aid in healing by increasing oxygen levels and helping to regulate body temperature. Celliant is now available in a variety of products for the sleep, sport, health and life markets.

About Hologenix
Hologenix, LLC, maker of Celliant, is committed to creating, discovering and marketing products that enhance people's lives through pain relief, increased comfort and improved overall well-being. The research that led to the creation of Celliant began in the 1990s when a team of pioneers in the field of alternative medicine visited Asia and observed the use of several natural substances that were thought to have a positive effect on health. After seven years of research and study, the team was able to integrate some of these materials into fabrics that could be made into apparel, bedding and medical products. Hologenix was founded in order to commercialize and bring this material, known as Celliant, to market. The Celliant formulation is patent protected.

###

Read the full story at http://www.prweb.com/releases/Celliant/PainStudy/prweb2567504.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Radiologists encouraged to look beyond cancer for clinically unseen diseases
2. Clinical depression linked to abnormal emotional brain circuits
3. Preclinical study suggests organ-transplant drug may aid in lupus fight
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Good Clinical Practice Journal Awards: Winners Announced
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Study Questions Dead-End Cancer Clinical Trials
8. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
9. Clinical trials present better alternatives for dialysis patients
10. Mirixa Debuts New Clinical Technology Solutions for Enhancing Patient Care
11. IMPACT initiative looks to improve patient participation in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical Study Data Indicates that Celliant Reduces Pain
(Date:2/27/2017)... , ... February 27, 2017 , ... The threat of ... to work for a company involved in the underground testing of nuclear weapons. Years ... for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical ...
(Date:2/27/2017)... ... 2017 , ... Orange County dentist, Dr. A. Rassouli, comments on ... when the bacteria in plaque infect the gums and other tissues supporting the teeth. ... planing or SRP, and can include surgical therapies if the condition has led to ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate smart media ... system brings songs, movies, TV shows and much more apps for user exploration. Its ... An immersive view of 1280 x 720 provides crisp images with remarkable clarity and ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... threshold mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count ... in March 2014. The company had 800 customers and 2,250 RCEs at the ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... for hair transplantation therapy, is proud to announce a new informational post on ... therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation (FUT) ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Md. , Feb. 27, 2017  RegeneRx ... a clinical-stage drug development company focused on tissue ... licensee for RGN-137, GtreeBNT Co., Ltd., received a ... Phase 3 clinical trial design for RGN-137 to ... wound healing gel that incorporates Thymosin beta 4 ...
(Date:2/27/2017)... 27, 2017 A recent research report published ... market alone is expected to reach a value of $55.8 billion ... along with 28 states have legalized marijuana for medical uses. In ... Florida , North Dakota , ... to use the drug in medical applications such as chemotherapies and ...
(Date:2/27/2017)... N.J. and PETACH TIKVAH, Israel ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... appointments of June S. Almenoff , M.D., Ph.D., ... to its Board of Directors.  "Dr. ... executives whose appointments come at an exciting time for ...
Breaking Medicine Technology: